<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1745">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395105</url>
  </required_header>
  <id_info>
    <org_study_id>1264</org_study_id>
    <nct_id>NCT04395105</nct_id>
  </id_info>
  <brief_title>Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial</brief_title>
  <official_title>High Versus Low Dose Dexamethasone for the Treatment of COVID-19 Related ARDS: a Multicenter and Randomized Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is compelling data indicating that there is an excessive inflammatory response in some
      patients with COVID-19 leading them to develop ARDS that can be severe with a very poor
      prognosis. Many of these patients require very long mechanical ventilation times to survive,
      which have led to the collapse of the health system in some regions of the world. The current
      evidence for the treatment of these severe forms is inconsistent and most scientific
      societies and governmental or international organizations recommend evaluating treatments
      with randomized clinical trials. Corticosteroids, being non-specific anti-inflammatory drugs,
      could shorten the duration of respiratory failure and improve the prognosis. Due to the lack
      of solid data available regarding this serious disease, our objective is to randomly evaluate
      the efficacy and safety of the use of dexamethasone, a parenteral corticosteroid approved in
      Argentina, in patients with ARDS with confirmed respiratory infection due to SARS-CoV-2
      (COVID-19).

      After RECOVERY trial prepublication, low dose (6 mg QD for 10 days) dexamethasone was
      recommended as the usual care treatment for severe COVID-19. At this time only 3 patients had
      been included in the trial. Thus, we updated our recommendations for centers and decided to
      compare two different doses of this glucocorticoid for the treatment of ADRS due to COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days at 28 days</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Days without ventilator support in the first 28 days following randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-days mortality</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Dead rate within 28 days of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of nosocomila infections</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Frequency of ventilator associated pneumonia, blood stream infection or candidemia in the first 28 days following randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral shedding</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Frequency of positive PCR on nasopharingeal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-reactive Protein variation</measure>
    <time_frame>10 days after randomization</time_frame>
    <description>Change from baseline CPR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA variation</measure>
    <time_frame>10 days after randomization</time_frame>
    <description>Variation in SOFA over the first 10 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of prone position</measure>
    <time_frame>10 days after randomization</time_frame>
    <description>Cumulative hours spent on prone position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Frequency of delirium at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle weakness</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>mMRC score at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Death rate within 90 days of randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>High dose Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 mg qd from day 1 to 5 followed by 8 mg qd from day 6 to 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care with Low dose Dexamethasone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual treatment without using up to 6 mg qd of dexamethasone for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone (high dose)</intervention_name>
    <description>IV Dexamethasone administered once daily: 16 mg from day 1 to 5 and 8 mg from day 6 to 10</description>
    <arm_group_label>High dose Dexamethasone</arm_group_label>
    <other_name>Corticosteroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ARDS according to Berlin's definition

          -  PCR confirmed COVID-19

          -  Length of mechanical ventilation less or equal to 72 hours

        Exclusion Criteria:

          -  Pregnancy

          -  Terminal illness with very poor prognosis according to the investigator judgement

          -  Do-not-resucitate order

          -  Known immunocompromised condition

          -  Chronic use of systemic corticosteroids

          -  Abscence of informed consent

          -  Active participation in other randomized clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo O Rodriguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis P Maskin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo O Rodriguez, MD</last_name>
    <phone>+541152990100</phone>
    <phone_ext>4307</phone_ext>
    <email>prodriguez@cemic.edu.ar</email>
  </overall_contact>
  <location>
    <facility>
      <name>CEMIC (Centro de Educación Médica e Investigaciones Clínicas)</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>1431</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo O Rodriguez, MD</last_name>
      <phone>1152990100</phone>
      <phone_ext>4307</phone_ext>
      <email>prodriguez@cemic.edu.ar</email>
    </contact>
    <contact_backup>
      <last_name>Stella Zarza, SC</last_name>
      <phone>1152990100</phone>
      <phone_ext>2543</phone_ext>
      <email>szarza@cemic.edu.ar</email>
    </contact_backup>
    <investigator>
      <last_name>Pablo O Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis P Maskin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignacio Bonelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio Sagrado Corazon</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Olarte, MD</last_name>
      <email>glolarte@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gabriel Olarte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalio Baredes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Bazterrica</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Palizas</last_name>
      <email>fernandopalizas@yahoo.com.ar</email>
    </contact>
    <investigator>
      <last_name>Fernando Palizas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 16, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno</investigator_affiliation>
    <investigator_full_name>Pablo Oscar Rodriguez</investigator_full_name>
    <investigator_title>Pulmonary and Critical Care Coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

